What are peptides and why is everyone taking them?
Peptides are everywhere in wellness — from GLP-1s to BPC-157. Here’s what they are, why they’re trending, and what the clinical evidence shows.
August 13, 2026
Beyond Weight Loss: The Potential Benefits of GLP-1s
GLP-1s have moved far beyond weight loss. Here’s what the latest research shows about their effects on heart, kidneys, liver, sleep, brain, and cravings.
Category:
Health
What started as a conversation about weight loss has quickly expanded into something much bigger.
The same molecules helping people lose weight are also potentially:
- Protecting hearts
- Slowing kidney disease
- Treating fatty liver
- Fixing sleep apnea
- Easing addictive cravings
That shift matters because it changes how we think about these drugs. GLP-1s are no longer being discussed as only tools for body composition, but as medications with that offer much more.
How can one drug class do so much?
Think of GLP-1s as your body’s multitaskers. Yes, they suppress your appetite and slow down digestion. But they also interact with systems throughout the body.
GLP-1 receptors live in your:
- Pancreas
- Stomach
- Gut
- Kidneys
- Heart
- Brain
- Blood vessels
When you activate them, you change how a lot of different systems communicate at once.
The result? Metabolic ripples that move far beyond weight. You might see insulin sensitivity improve, inflammation go down, blood vessels relax, cravings ease, sleep shift, or the brain’s reward pathways recalibrate.
Here’s what the clinical research is showing.
What GLP-1s can now support (beyond weight loss)
1. Your heart
Cardiovascular disease has been the leading cause of death in the U.S. for over a century, and obesity is one of its biggest accelerants
For most of that time, the treatment plan has been the same: statins, blood pressure meds, lifestyle change. Then came the SELECT trial, which started in 2018 and concluded in 2023.
The trial looked at nearly 18,000 patients with overweight or obesity and existing cardiovascular disease, gave half of them Wegovy, and followed them for over three years. The result was a 20% reduction in major cardiovascular events.
This data led the FDA to approve Wegovy in March 2024 for reducing the risk of cardiovascular events in adults with obesity or overweight who also had cardiovascular disease. So this means that Wegovy is now formally a cardioprotective drug.
GLP-1s are no longer just an option for weight loss.
2. Your kidneys
Chronic kidney disease affects about 1 in 7 American adults, and it gets worse on average faster than almost any other chronic condition. Once it progresses past a certain point, dialysis or transplant is the only path forward.
Enter: the FLOW trial (2019-2024). It enrolled over 3,000 adults with type 2 diabetes and chronic kidney disease. Half of the participants got semaglutide and were followed for about 3.5 years.
The results found a 24% reduction in major kidney disease events like:
- Kidney failure
- Kidney-related death
- Cardiovascular death
This is a major shift in what these drugs can offer to people managing diabetes or with early kidney issues.
3. Your sleep
About 30 million Americans live with obstructive sleep apnea — a condition where breathing stops repeatedly during sleep, blood oxygen drops, and the heart pays the price over the years.
Until recently, the only real treatments were a CPAP machine, surgery, or major weight loss.
Then, in December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe sleep apnea in adults with obesity. It’s the first medication ever approved specifically for OSA. The trial behind that approval (SURMOUNT-OSA) showed up to a 62.8% reduction in apnea-hypopnea events after just one year of use.
For people dragging through their days because they can't get past stage 1 sleep, this is a game-changer.
4. Your liver
Fatty liver disease is one of the fastest-growing chronic conditions in this country, and the inflammatory form, MASH, has historically had almost no pharmacological treatment.
It affects about 6 to 8 million Americans whose fatty liver disease has progressed to significant fibrosis (scarring). And for years, the only intervention that seemed to make any changes was weight loss.
Then two FDA approvals happened back-to-back. In August 2025, Wegovy (semaglutide) was approved for metabolic dysfunction-associated steatohepatitis (MASH). That approval was based on clinical trial data. And Zepbound (tirzepatide) followed in early 2026 thanks to results from the SYNERGY-NASH trial.
This is major because fatty liver disease used to have almost no pharmacological treatment options. Now it has two FDA-approved ones in the GLP-1 class.
5. Your cravings
It’s no secret that GLP-1s reduce your appetite and cravings for food. But what’s less widely known is that they do more than that.
The same dopamine and reward pathways driving food cravings also drive cravings for alcohol, nicotine, gambling, and other compulsive behaviors. And guess what? Those cravings appear to ease on GLP-1s, too.
A 2025 trial showed once-weekly semaglutide reduced alcohol craving and certain drinking outcomes in adults with alcohol use disorder. And this supports the larger trials that are currently happening.
Smaller studies and real-world observational data show similar effects on nicotine, gambling, food noise, and more. The biology is still being mapped, but the signal is consistent enough that addiction medicine has started taking GLP-1s seriously as a tool.
6. Your brain
Alzheimer’s is a condition where progress has been incredibly hard to make. Most of the major drug candidates in the last 20 years have failed in late-stage trials. So when oral semaglutide entered Phase 3 trials for early Alzheimer’s, neurology took notice. And here’s the hypothesis.
GLP-1s might:
- Reduce neuroinflammation
- Improve insulin signaling in the brain
- Dampen amyloid accumulation
- Slow cognitive decline
We’re expecting to see the results of these trials in late 2026. And if the data lands, this would be a truly meaningful new tool in a field that has very few of them.
What’s coming next
There’s a lot in motion right now.
GLP-1s are in active Phase 3 trials for:
- Heart failure with preserved ejection fraction (the obesity-linked form of heart failure that’s been hardest to treat)
- Polyendocrine metabolic ovarian syndrome (PMOS) Polycystic ovary syndrome (PCOS)
- Autoimmune conditions like psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease
- Type 1 diabetes
- Peripheral artery disease
Most of these will have FDA decisions between 2026 and 2028. But it’s evident that GLP-1s have grown into one of the most versatile drug classes in modern medicine.
What this means for your practice
GLP-1s have grown well past their original framing as a weight loss tool. Today, they’re a topic in metabolic health, cardiovascular risk, neurological pathways, and behavior change. And FDA approvals continue to expand across multiple uses.
This shift changes the way you talk to clients. It changes which clients might benefit from GLP-1s. And it changes how you think about peptide therapy in your practice as a whole.
Here’s what that can look like in practice:
→ A client comes in asking about Ozempic for weight loss.
→ You ask about their sleep, their cravings, their family history of cardiovascular disease, and their last lipid panel.
→ The conversation opens up.
→ And suddenly, you’re talking about whole-body metabolic health, with GLP-1s as one of the many tools you can bring to it.
That’s the next era of wellness practice. And it’s the kind of care that builds client relationships that last.
FAQs
Do GLP-1s only work if you’re trying to lose weight?
No. The FDA-approved indications now include:
- Cardiovascular disease risk reduction
- Chronic kidney disease progression in type 2 diabetes
- Obstructive sleep apnea
- MASH (the inflammatory form of fatty liver disease)
The medical literature also shows promising effects in addiction, fertility (especially PCOS), and maybe even cognitive function.
Are the benefits beyond weight loss dependent on losing weight?
Some are, some aren’t. The cardiovascular protection in trials showed up earlier than weight loss alone would predict, which suggests direct cardiac effects.
The same thing with the trial for kidney protection. Liver and sleep apnea benefits do track with weight loss, but research suggests they go further than weight loss alone would explain.
Should clients consider GLP-1s for those other conditions specifically?
That’s a clinical decision that requires physician evaluation. The conditions vary a lot in severity, and GLP-1s work better for some than others. The expanded FDA indications do mean it’s a legitimate conversation to bring up with a licensed clinician.
Are these benefits long-term?
The longest GLP-1 outcome trials run 3 to 5 years. Most of the cardiovascular, kidney, and metabolic benefits appear to last as long as the drug is taken. What happens when patients stop is a separate (and very important) question. Currently, most metabolic benefits do reverse over time without ongoing treatment.
The bigger picture
The story of GLP-1s started with diabetes. Then it became about weight loss. Now it’s about something much bigger.
One drug class and half a dozen organ systems. A growing list of FDA approvals and research that keeps adding to what these molecules can do.
Maybe your clients have heard about the cardiovascular data. Maybe they’ve heard about the kidney findings. Maybe they’re starting to read about GLP-1s for sleep apnea and even alcohol cravings.
The question is whether you can provide them with real clinical answers, or whether you have to send them somewhere else.
Altro Health was built so that wellness businesses don’t have to send clients away when those conversations happen. Through one platform, you connect to:
- Clinicians who prescribe across the full range of GLP-1 uses
- Pharmacies that compound under USP standards
- The lab and monitoring infrastructure that keeps dosages personalized
Your clients stay connected to your brand while the clinical care is managed by licensed clincians.
As the science on GLP-1s keeps advancing, the practices that grow with it are the ones clients are most likely to return to.
Sources
Obstructive sleep apnea | Mayo Clinic
Learn About Sleep Apnea | American Lung Association
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder | JAMA Psychiatry
Related blogs
wellness designed for growth
expand your business and give more to your clients.
